These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18431244)

  • 1. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus.
    Dean PG; Grande JP; Sethi S; Park WD; Griffin MD; Cosio FG; Larson TS; Stegall MD
    Transplantation; 2008 Apr; 85(8):1212-5. PubMed ID: 18431244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal.
    Heilman RL; Cortese C; Geiger XJ; Younan K; Wadei HM; Mai ML; Reddy KS; Gonwa TA
    Transplantation; 2012 Jan; 93(1):47-53. PubMed ID: 22067270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus.
    Morales JM; Grinyó JM; Campistol JM; García-Martínez J; Arias M; Paul J; Sánchez-Fructuoso A; Brunet M; Granados E; Munoz-Robles JA
    Transplantation; 2008 Aug; 86(4):620-2. PubMed ID: 18724234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation.
    Yang YJ; Li LX; He Q; Fan H; Jin ZK; Lang R; Kou JT; Li P; Xie DH; Chen DZ
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):376-8. PubMed ID: 17690032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressive regimen and interstitial fibrosis and tubules atrophy at 12 months postrenal transplant.
    Gelens MA; Steegh FM; van Hooff JP; van Suylen RJ; Nieman FH; van Heurn LW; Peutz-Kootstra CJ; Christiaans MH
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):1010-7. PubMed ID: 22490875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical factors associated with graft fibrosis in kidney-transplant recipients on steroid-avoidance immunosuppression.
    Heilman RL; Chakkera HA; Reddy KS; Colby TV; Moss AA; Williams JW; Mazur MJ; Petrides S; Mulligan DC
    Clin Transplant; 2008; 22(3):309-15. PubMed ID: 18482051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies.
    Cosio FG; Amer H; Grande JP; Larson TS; Stegall MD; Griffin MD
    Transplantation; 2007 Feb; 83(4):411-6. PubMed ID: 17318073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness.
    Chan L; Greenstein S; Hardy MA; Hartmann E; Bunnapradist S; Cibrik D; Shaw LM; Munir L; Ulbricht B; Cooper M;
    Transplantation; 2008 Mar; 85(6):821-6. PubMed ID: 18360262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious.
    Meiser B; Kaczmarek I; Mueller M; Groetzner J; Weis M; Knez A; Stempfle HU; Klauss V; Schmoeckel M; Reichart B; Ueberfuhr P
    J Heart Lung Transplant; 2007 Jun; 26(6):598-603. PubMed ID: 17543783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients.
    Toso C; Morel P; Bucher P; Mathe Z; Demuylder-Mischler S; Bosco D; Berney T; Oberholzer J; Shapiro J; Oberholzer J; Philippe J
    Transplantation; 2003 Oct; 76(7):1133-4. PubMed ID: 14557767
    [No Abstract]   [Full Text] [Related]  

  • 19. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease.
    Couriel DR; Saliba R; Escalón MP; Hsu Y; Ghosh S; Ippoliti C; Hicks K; Donato M; Giralt S; Khouri IF; Hosing C; de Lima MJ; Andersson B; Neumann J; Champlin R
    Br J Haematol; 2005 Aug; 130(3):409-17. PubMed ID: 16042691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus monotherapy effectiveness in liver transplant recipients with renal dysfunction due to calcineurin inhibitors.
    Di Benedetto F; Di Sandro S; De Ruvo N; Spaggiari M; Montalti R; Ballarin R; Cappelli G; Gerunda GE
    J Clin Gastroenterol; 2009 Mar; 43(3):280-6. PubMed ID: 19057397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.